PWP1在肝細胞癌中過表達,促進肝癌細胞增殖

 二維碼
發表時間:2024-08-21 17:02

2024年6月,生物化學與分子生物學系,重大疾病共機制研究國家重點實驗室,基礎醫學院中國醫學科學院,北京協和醫科大學基礎醫學院,北京100005,內蒙古醫科大學附屬醫院中國臨床醫學研究中心,內蒙古醫學細胞生物學重點實驗室a Department of Biochemistry and Molecular Biology, State Key Laboratory of Common Mechanism Research for Major Diseases, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, 100005, China b Clinical Medical Research Center of the Affiliated Hospital, Inner Mongolia Medical University, Inner Mongolia Key Laboratory of Medical Cell

Biology, 1 Tong Dao Street, Hohhot, 010050, Inner Mongolia, China )Wei Song.a 研究團隊在《Heliyon》上發表論文:

PWP1 is overexpressed in hepatocellular carcinoma and facilitates liver cancer cell proliferation


PWP1在肝細胞癌中過表達,促進肝癌細胞增殖


Abstract


Identification of novel biomarkers for prediction of disease course and prognosis is needed to reduce morbidity of liver hepatocellular carcinoma (LIHC/HCC) patients. Although dysregulated Periodic tryptophan protein 1 homolog (PWP1/endonuclein) expression has been detected in several tumors, the potential regulatory effect of PWP1 on LIHC remains uncertain. Here we evaluated the expression of PWP1 using multiple online platforms, and demonstrated that PWP1 upregulation was consistently observed in LIHC relative to non-tumor liver tissues and correlated with unfavorable prognosis. Moreover, HCC prognosis was significantly influenced by the

methylation status of various CpG sites in the PWP1 gene. Lastly, we provide direct evidence that PWP1 acts as a driver of HCC progression by showing that siRNA-mediated PWP1 silencing significantly suppressed HCC cell proliferation in vitro. These data strongly suggest that PWP1 silencing may be an effective therapeutic strategy to treat LIHC.


摘要:

為了降低肝細胞癌(LIHC/HCC)患者的發病率,需要鑒定新的生物標志物來預測病程和預后。盡管在幾種腫瘤中檢測到周期性色氨酸蛋白1同源物(PWP1/內核素)表達異常,但PWP1對LIHC的潛在調節作用仍不確定。本研究中,研究人員利用多個在線平臺評估了PWP1的表達,結果表明,相對于非腫瘤肝組織,PWP1在LIHC中一致表達上調,并與不良預后相關。此外,HCC預后受PWP1基因中各種CpG位點甲基化狀態的顯著影響。最后,科研人員通過sirna介導的PWP1沉默在體外顯著抑制HCC細胞增殖,提供了PWP1作為HCC進展驅動因素的直接證據。這些數據強烈提示PWP1沉默可能是治療LIHC的有效治療策略。


該論文中,人肝癌細胞系(Huh7、HepG2、PLC和SMMC7721)細胞的體外培養是使用Ausbian特級胎牛血清完成的欲了解或購買Ausbian特級胎牛血清可以聯系北京締一生物400-166-8600.



相關閱讀
最新動態